LAV

Ronovo Surgical advances commercialization in China through Targeted Collaboration Agreement with Johnson & Johnson

2025年9月6日

Shanghai, China – September 5, 2025 – Ronovo Surgical, a global innovator in next-generation...

Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China’s first hemophilia B gene therapy, was officially approved

2025年4月11日

Shanghai, China, April 10, 2025 – Belief BioMed ("BBM") and Takeda China today jointly announced...

Syneron Bio Announces Strategic Collaboration with AstraZeneca

2025年3月21日

BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug...

Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer

2025年1月17日

SHANGHAI, January 16th, 2025 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery

2025年1月13日

[January 13, 2025] – Cornerstone Robotics (the “Company”), a leading global innovator in surgical...

Alebund Pharmaceutical announced the first closing of RMB 550 million in Series C financing

2025年1月7日

January 7, 2025, Alebund Pharmaceuticals (“Alebund” or the “Company”), an integrated...

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

2024年12月18日

MIAMI--(BUSINESS WIRE)--Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today...

AGAMREE® for DMD Treatment was Approved by China’s NMPA

2024年12月11日

December 11, 2024, Sperogenix Therapeutics announced that, AGAMREE® (vamorolone) was approved by...

Duality Biologics and GSK Enter into Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)

2024年12月4日

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 3, 2024 /PRNewswire/ -- Duality Biologics (...

IMPACT Announces Completion of RMB 250 million Sr. D++ Financing

2024年11月15日

SHANGHAI, November 15th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline

2024年10月29日

CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B...

Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer

2024年9月30日

Cambridge, Massachusetts, September 30, 2024 - Regor Pharmaceuticals (USA) ("Regor") has entered...

ImmuneOnco and Instil Bio Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

2024年8月2日

Shanghai, China and Dallas, TX, August 01, 2024 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ...

Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms

2024年7月19日

- Financing led by LongRiver Investments with participation by new and existing global...

AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease

2024年6月13日

- Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the...

Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment

2024年5月16日

Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to...

The Phase 3 clinical trial data of Senaparib published in Nature Medicine, positioning it as a promising first-line maintenance treatment option for the all-comer population in advanced ovarian cancer

2024年5月15日

On May 15, 2024, the internationally renowned medical journal Nature Medicine (Latest impact...

Impact Raises RMB 400 million in Series D+ Funding

2024年4月19日

SHANGHAI, April 19th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

2024年4月4日

Genmab to acquire ProfoundBio for USD 1.8 billion in cashAcquisition will give Genmab...

NDA of AGAMREE was Accepted and Granted Priority Review by China’s CDE

2024年3月26日

March 26, 2024, the NDA filling of AGAMREE (vamorolone) is indicated for the treatment of...

All Categories - LAV